Mavacamten, sold under the brand name Camzyos, is a medication used to treat obstructive hypertrophic cardiomyopathy. Mavacamten is a small-molecule allosteric...
19 KB (1,217 words) - 01:27, 28 March 2024
Levomilnacipran Lisuride Lithium Loperamide Loxapine Lumiracoxib Lurasidone Mavacamten Maprotiline Meclofenoxate Mephenoxalone Mefexamide Memantine Mepazine...
26 KB (1,685 words) - 02:08, 21 February 2024
number of active actin–myosin cross-bridges within the myocyte sarcomere. Mavacamten was shown to reduce left ventricular outflow tract gradient (a measure...
82 KB (8,831 words) - 23:34, 21 July 2024
company MyoKardia for $13.1 billion ($225 per share) gaining control of mavacamten, a cardiovascular drug for obstructive hypertrophic cardiomyopathy (HCM)...
96 KB (7,620 words) - 00:01, 16 August 2024
voriconazole (antifungal) tamoxifen (selective estrogen receptor modulator) mavacamten (hypertrophic cardiomyopathy inhibitor) Strong fluconazole (antifungal)...
39 KB (3,879 words) - 02:14, 11 August 2024
(mCRPC) Alpelisib Novartis PIK3CA-related overgrowth spectrum conditions Mavacamten Myokardia Inc class II-III obstructive hypertrophic cardiomyopathy Trastuzumab...
34 KB (180 words) - 22:09, 8 April 2024
2020-06-26. Retrieved 2020-06-24. "Myokardia posts positive phase III for mavacamten". www.bioworld.com. Retrieved 2020-07-06. "3 Biotech Stocks Surging on...
9 KB (608 words) - 13:34, 12 April 2024
Ranolazine C01EB21 Regadenoson C01EB22 Meldonium C01EB23 Tiazotic acid C01EB24 Mavacamten QC01EB90 Sirolimus Class II antiarrhythmics (beta blocking agents) are...
6 KB (550 words) - 02:50, 18 December 2023